Cubist Systematic Strategies LLC Invests $3.15 Million in Immunocore Holdings plc (NASDAQ:IMCR)

Cubist Systematic Strategies LLC purchased a new stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 106,600 shares of the company's stock, valued at approximately $3,145,000. Cubist Systematic Strategies LLC owned approximately 0.21% of Immunocore as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its stake in shares of Immunocore by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after acquiring an additional 960 shares in the last quarter. NEOS Investment Management LLC raised its stake in shares of Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after acquiring an additional 1,102 shares in the last quarter. Virtus ETF Advisers LLC raised its stake in shares of Immunocore by 39.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock worth $340,000 after acquiring an additional 3,238 shares in the last quarter. XTX Topco Ltd raised its stake in shares of Immunocore by 22.2% during the 4th quarter. XTX Topco Ltd now owns 18,896 shares of the company's stock worth $557,000 after acquiring an additional 3,437 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of Immunocore by 2,044.0% during the 4th quarter. Barclays PLC now owns 20,625 shares of the company's stock worth $608,000 after acquiring an additional 19,663 shares in the last quarter. Institutional investors own 84.50% of the company's stock.

Immunocore Stock Performance

Shares of IMCR stock traded up $0.91 during trading hours on Friday, hitting $29.97. The company's stock had a trading volume of 190,188 shares, compared to its average volume of 299,216. The company has a 50 day moving average of $28.71 and a 200 day moving average of $30.06. The stock has a market cap of $1.50 billion, a PE ratio of -31.55 and a beta of 0.75. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore Holdings plc has a 12-month low of $23.15 and a 12-month high of $55.07.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.45. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business had revenue of $125.13 million for the quarter, compared to the consensus estimate of $108.82 million. During the same period in the prior year, the firm earned ($0.49) EPS. The business's revenue for the quarter was up 33.6% on a year-over-year basis. On average, sell-side analysts forecast that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IMCR has been the topic of several research analyst reports. Morgan Stanley reissued an "equal weight" rating and set a $35.00 target price on shares of Immunocore in a research report on Friday, March 7th. JPMorgan Chase & Co. dropped their target price on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a research report on Monday, April 14th. Needham & Company LLC reissued a "buy" rating and set a $71.00 target price on shares of Immunocore in a research report on Thursday, April 10th. Oppenheimer boosted their target price on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Finally, Mizuho dropped their target price on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat, Immunocore has a consensus rating of "Moderate Buy" and an average price target of $58.13.

Insider Buying and Selling

In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the firm's stock in a transaction on Monday, March 17th. The shares were acquired at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the acquisition, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This trade represents a 60.40% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.40% of the stock is currently owned by insiders.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.